Study: ICU May Be Overused for Some COPD, Acute MI, HF Patients
For patients with COPD, heart failure and myocardial infarction, who are not critically ill, a stay in the ICU may be no more beneficial than staying on a ward, according to an analysis just published in the Annals of the ATS.
Thomas Valley, MD, MSc, a pulmonary and critical care researcher at the University of Michigan Medical School, and colleagues, analysed more than 1.5 million Medicare records. They estimated that approximately one in six patients was admitted to the ICU only because of living closest to a hospital that places a high percentage of its patients in ICU beds.
See Also: Study: More than Half of ICU Admissions May Be Inappropriate
The researchers looked at 30-day mortality and also at cost of care. "We wanted to evaluate whether ICU care is always beneficial," said Valley, in a media release. "ICU care can save lives, but it is also very costly."
There was no difference in mortality between patients treated in the ICU and those treated as regular inpatients. As might be expected, however, the cost of ICU care for heart failure exacerbation was significantly higher ($2,608 more) and heart attack ($4,922 more) than regular inpatient care. There was no difference in the cost of treating COPD patients between the two settings.
Dr. Valley noted that their findings show that the ICU may not always be the answer for this group of patients, adding: “Now, we need to help doctors decide who needs the ICU and who doesn't."
Study limitations include the fact that only Medicare patients were part of the study so results may not apply to younger patients. Costs include only hospital charges, not physician fees.
The authors concluded, "These findings suggest that the ICU may be overused for some COPD, heart failure, or acute myocardial infarction patients with an uncertain indication for intensive care, and opportunities exist to decrease health care costs by reducing ICU admissions for certain patients."
Source and image credit: American Thoracic Society
Published on : Fri, 17 Feb 2017
Always in sight, always in mind Features Mindray believes the best way to predict the future is to create it. The revolutionary BeneVision N22/N19 is designed to optimize user experience by satisfying all your clinical demands. With visionary-stimulating...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for...
Q-NRG is the first Indirect Calorimeter specifically intended for the measurement of Resting Energy Expenditure (REE) in patients who are mechanically ventilated or spontaneously breathing and for healthy subjects. Q-NRG is a unique product, resulting...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...